[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100441390":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":96,"collaborators":99,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":18,"eligibilityCriteria":108,"healthyVolunteers":104,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":18,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Jewish General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Early Ileostomy Closure","EXPERIMENTAL","Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.",[13],"Procedure: Early Ileostomy Closure",{"label":15,"type":16,"description":17,"interventionNames":18},"Traditional closure (control)","NO_INTERVENTION","Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo a standardized reversal of their diverting loop ileostomy. The latter will be performed with a stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia and will be performed no earlier than 12 weeks following their index surgery.",null,[20],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":18},"PROCEDURE",[9],[24,30],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"Natasha Caminsky, MD","CONTACT","514-340-8222","25996","natasha.caminsky@mail.mcgill.ca",{"name":31,"role":26,"phone":27,"phoneExt":28,"email":32},"Sarah Sabboobeh, MSc","sarah.sabboobeh@ladydavis.ca",[34,55,70,84],{"facility":35,"status":36,"city":37,"state":38,"zip":18,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"St. Paul's Hospital, Providence Health Care","RECRUITING","Vancouver","British Columbia","Canada","CA",{"type":42,"coordinates":43},"Point",[44,45],-123.11934,49.24966,{"lat":45,"lon":44},[48,49,53],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},{"name":50,"role":26,"phone":51,"phoneExt":18,"email":52},"Amandeep Ghuman, MD, MPH, FRCSC","604-806-8860","aghuman@providencehealth.bc.ca",{"name":50,"role":54,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"facility":56,"status":36,"city":57,"state":58,"zip":18,"country":39,"countryCode":40,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"London Health Sciences Centre","London","Ontario",{"type":42,"coordinates":60},[61,62],-81.23304,42.98339,{"lat":62,"lon":61},[65,66,69],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},{"name":67,"role":26,"phone":18,"phoneExt":18,"email":68},"Nawar AlKhamesi, MD","Nawar.Alkhamesi@lhsc.on.ca",{"name":67,"role":54,"phone":18,"phoneExt":18,"email":18},{"facility":5,"status":36,"city":71,"state":72,"zip":73,"country":39,"countryCode":40,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Montreal","Quebec","H3T1E2",{"type":42,"coordinates":75},[76,77],-73.58781,45.50884,{"lat":77,"lon":76},[80,81,82],{"name":31,"role":26,"phone":27,"phoneExt":28,"email":32},{"name":25,"role":26,"phone":18,"phoneExt":18,"email":29},{"name":83,"role":54,"phone":18,"phoneExt":18,"email":18},"Marylise Boutros, MD",{"facility":85,"status":36,"city":71,"state":72,"zip":18,"country":39,"countryCode":40,"cosmosGeoPoint":86,"geoPoint":88,"contacts":89},"McGill University Health Centre",{"type":42,"coordinates":87},[76,77],{"lat":77,"lon":76},[90,91,94],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},{"name":92,"role":26,"phone":18,"phoneExt":18,"email":93},"Marie Demian, MSc","mariedemian@gmail.com",{"name":95,"role":54,"phone":18,"phoneExt":18,"email":18},"Sender Liberman, MD",{"type":54,"investigatorFullName":97,"investigatorTitle":98,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Dr. Marylise Boutros","Associate Professor",[100],{"name":101,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","100441390","early-ileostomy-closure-for-rectal-cancer-patients-in-north-america-100441390",false,"NCT05027737","Early Ileostomy Closure for Rectal Cancer Patients in North America","Early Ileostomy Closure Following Restorative Proctectomy for Rectal Cancer Patients: A North American Multicenter Randomized-Controlled Trial (RCT)","Inclusion Criteria:\n\n* Adult (≥18 years-old) patients\n* Underwent restorative proctectomy by a laparoscopic, robotic, transanal total mesorectal excision, or open approach with creation of a diverting loop ileostomy for the treatment of rectal cancer\n* Negative anastomotic \"leak test\" via CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9.\n\nExclusion Criteria:\n\n* Peri-operative immunosuppression (within 6 weeks of surgery date);\n* Age-adjusted Charlson Comorbidity Index \\>6;\n* Other major surgery during the index operation;\n* Any major complications (Clavien Dindo Grade III or greater) following restorative proctectomy;\n* Inability to speak or comprehend English or French and inability to give informed consent.","FEMALE","18 Years","90 Years",{"count":113,"type":114},118,"ESTIMATED","INTERVENTIONAL",[117],"NA","Our preliminary work demonstrates that there is buy-in from both patients and surgeons with regards to early ileostomy closure (EIC) for select rectal cancer patients undergoing restorative proctectomy (RP) and diverting loop ileostomy (DLI). The feedback from leaders in Europe further supports the need for a large scale randomized-controlled trial (RCT) on this subject in North America. Should the results of such a study be favourable, we believe it could support a change in practice that would be beneficial to patients and the health care system alike. Furthermore, our work will help identify which patients and practices are suitable for EIC.\n\nThe goal of our project is to determine whether EIC in rectal cancer patients undergoing RP with a DLI is safe, feasible and beneficial in a North American population. Specifically, our primary objective is to compare the severity of complications between patients undergoing EIC versus traditional (late) closure. Our secondary objectives include assessing the difference in quality of life (QoL), early and late bowel function, and cost of care between these two groups.",[120,121],"Ileostomy - Stoma","Rectal Cancer",[123,124,125,126,127,128],"Early ileostomy closure","Comprehensive complication index","Bowel function","Quality of life","Recovery","Cost","2022-08-22",{"date":131,"type":132},"2022-08-23","ACTUAL",{"date":134,"type":132},"2022-02-22",{"date":136,"type":114},"2026-09-01",{"name":5,"class":6},4]